drugset

drugset / Trial / NCT07219511

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT07219511 ↗

Phase 1 Recruiting 42 enrolled Vasa Therapeutics

RandomizedParallel-groupTriple-blindTreatment

Summary

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Timeline

Start: 2025-11-04
Primary completion: 2026-06
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VS-041	Unknown	—	Oral

Indications